



# Farmacia HOSPITALARIA

Órgano oficial de expresión científica de la Sociedad Española de Farmacia Hospitalaria



## ORIGINALS

Bilingual edition English/Spanish

### Negative pressure therapy with instillation for the treatment of infected wounds: recommendations of utilization based on evidence

#### Terapia de presión negativa con instilación para el tratamiento de heridas infectadas: recomendaciones de utilización basadas en la evidencia

Clara Cortell-Fuster<sup>1</sup>, Marisa Gaspar-Carreño<sup>2</sup>, Rubén Achau-Muñoz<sup>2</sup>,  
Trinidad Delgado-Ruiz<sup>3</sup>, Ana Hortelano-Otero<sup>3</sup>

<sup>1</sup>Servicio de Farmacia, Hospital Universitario Doctor Peset, Valencia, Spain. <sup>2</sup>Servicio de Farmacia, Hospital Interhospital de Levante, Sant Antoni de Benaxeve, Valencia, Spain. <sup>3</sup>Servicio de Cirugía Plástica y Reparadora, Hospital Interhospital de Levante, Sant Antoni de Benaxeve, Valencia, Spain.

## Author of correspondence

Clara Cortell-Fuster  
Servicio de Farmacia,  
Hospital Universitario Dr. Peset.  
Avda. Gaspar Aguilar, 90.  
46017, Valencia, Spain

Correo electrónico:  
cortell\_cla@gva.es

Received 1 March 2018;  
Accepted 22 April 2018.

DOI: 10.7399/fh.11011

## How to cite this paper

Cortell-Fuster C, Gaspar-Carreño M, Achau-Muñoz R, Delgado-Ruiz T, Hortelano-Otero A. Negative pressure therapy with instillation for the treatment of infected wounds: recommendations of utilization based on evidence. Farm Hosp. 2019;43(1):6-12.

## Abstract

**Objective:** To establish recommendations related to negative pressure therapy with instillation according to effectiveness, safety, efficiency, consensus guidelines and stability data of instillation solutions.

**Method:** A literature search was conducted to compare the available evidence regarding effectiveness, safety and efficiency of negative pressure therapy with instillation, as well as the existence of consensus guidelines for use. The articles were classified according to the "Scale of evidence classification for therapeutic studies" of the American Society of Plastic and Reconstructive Surgery.

**Results:** A total of 13 studies were included, of which five were comparative cohort studies (level II and III of evidence), and the rest corresponded to case series (level IV of evidence). Two consensus guidelines were selected with recommendations regarding the type of wound, instillation solution, solution retention time, vacuum pressure and appropriate vacuum time. According to literature and available evidence, recommendations were proposed and established on negative pressure therapy with instillation in our hospital, including stability data of the proposed solutions.

**Conclusions:** This paper provides preliminary guidelines on the application of negative pressure therapy with instillation until new evidence supports or modifies these recommendations.

## Resumen

**Objetivo:** Establecer recomendaciones relacionadas con la terapia de presión negativa con instilación según efectividad, seguridad, eficiencia, guías de consenso y estabildades contrastadas de las soluciones de instilación.

**Método:** Se realizó una búsqueda bibliográfica para contrastar la evidencia disponible en cuanto a efectividad, seguridad y eficiencia de la terapia de presión negativa con instilación, así como la existencia de guías de consenso de utilización. Se clasificaron los artículos en función de la "Escala de clasificación de evidencia para estudios terapéuticos" según la Sociedad Americana de Cirugía Plástica y Reconstructiva.

**Resultados:** Se incluyeron 13 estudios, de los cuales cinco fueron estudios de cohortes comparativos (nivel II y III de evidencia), y el resto correspondieron a series de casos (nivel IV de evidencia). Se seleccionaron dos guías de consenso con recomendaciones según tipo de herida, solución de instilación, tiempo de retención de solución, presión de vacío y tiempo de vacío apropiado. Según la literatura y la evidencia disponible, se propusieron y establecieron recomendaciones sobre la terapia de presión negativa con instilación en nuestro hospital, incluyendo datos de estabilidad de las soluciones propuestas.

**Conclusiones:** Este manuscrito proporciona pautas preliminares para la aplicación de la terapia de presión negativa con instilación hasta que nuevas evidencias apoyen o modifiquen estas recomendaciones.

## KEYWORDS

Antimicrobials; Antiseptics; Instillation; Negative-Pressure; Wound; Evidence-Based Practice.

## PALABRAS CLAVE

Antibióticos; Antisépticos; Instilación; Presión-negativa; Herida; Práctica Basada en la Evidencia.



Los artículos publicados en esta revista se distribuyen con la licencia  
Articles published in this journal are licensed with a  
Creative Commons Attribution 4.0  
<https://creativecommons.org/licenses/by-nc-nd/4.0/>  
La revista Farmacia no cobra tasas por el envío de trabajos,  
ni tampoco por la publicación de sus artículos.

## Introduction

The treatment of infected and colonized wounds requires a multidisciplinary approach that includes, among other types of care, surgical debridement to remove necrotic and devitalized tissue, suitable systemic antibiotic treatment, and wound cleaning to eliminate the exudate, reduce the bacterial load, and encourage the formation of granulation tissue on the wound bed to close or cover it safely, depending on the complexity of the wound<sup>1</sup>.

Negative pressure wound therapy (NPWT) is of assistance in the treatment of wounds, because it promotes granulation of the wound bed, eliminates exudate, and prepares the wound for closure. The topical administration of solutions in combination with NPWT—known as negative pressure wound therapy with instillation (NPWTi)—further aids wound cleaning and microbial eradication.

The first known use of NPWT dates from 1550 BC in Egypt, where cupping therapy<sup>2</sup> was used to apply suction to the surface of wounds. There are also records of its use in China (1000 BC), and Hippocrates (400 BC) applied it to structural problems and skin diseases<sup>2</sup>.

In 1998, NPWT with antiseptic and antimicrobial solutions (NPTWi) was introduced to treat infected wounds unresponsive to conventional therapy<sup>3</sup>.

Currently, a range of NPWT and NPWTi devices are available. The NPWTi devices provide automated volumetric delivery of antiseptic or antimicrobial solutions. In this approach, instillation is alternated with negative pressure. NPWTi systems provide intermittent administration of a predefined amount of solution that remains on the wound for an amount of time set by the user before negative pressure is applied again. The level of accuracy provided by the devices has positioned NPWTi as a first-line therapy in the treatment of complex wounds.

The use of NPWT and NPWTi has proven benefits, which include the promotion of angiogenesis and granulation tissue formation, the stimulation of cellular and local blood flow, and the reduction of exudate and oedema. In addition, pain is reduced due to the elimination of lactic acid and the reduction of infectious burden. The wound is also enclosed in a moist and closed environment<sup>4</sup>.

Over the last 15 years, these therapies have improved the care of patients with chronic and acute wounds, and are currently a relevant tool for health care professionals. These therapies cover a wide range of clinical applications, of which the most relevant are prosthesis infection, surgical wounds or amputations, and pressure and diabetic foot ulcers.

However, there is limited evidence in the literature in support of their effectiveness, safety, and efficiency. Authors and health professionals support their use given their positive outcomes and cost reductions. Their support is based on reviews and experience in which NPWTi with antiseptics and NPWT were used; however, data on instillation with antibiotics are still very scarce. Likewise, there are few guidelines or recommendations based on consensual protocols that could standardise their use.

According to reported experience, the antiseptic solutions most commonly used were polyhexanide (0.005%-0.040% solution), acetic acid (0.25%-1.00% solution), and povidone-iodine (10% solution)<sup>5</sup>. Regarding antibiotic instillation, several authors have reported the use of bacitracin/neomycin<sup>6</sup>, polymyxin B/bacitracin<sup>7</sup>, vancomycin, gentamicin, and tobramycin<sup>8</sup>. In the United States, their use in NPWTi therapy is considered to be off-label<sup>9</sup>. The antimicrobial action of the instilled antibiotics or antiseptics is assumed to be local on the wound bed, with no evidence of systemic absorption.

This study was conducted in the setting of a Spanish Mutual Society Hospital that provides care to patients with workplace injuries. In 2017, the hospital performed 1,522 interventions in the Plastic and Reconstructive Surgery department and 4,130 interventions in the Orthopaedic and Traumatology Surgery department. In total, 6 patients with post-surgical wounds received NPWT and 7 received NPWTi. Four patients received antibiotic instillation therapy with colistin, gentamicin, and vancomycin after the isolation of microorganisms such as *Acinetobacter baumannii*, methicillin-resistant *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Proteus mirabilis*, and *Enterobacter cloacae*. The following aspects were not defined: vehicle, stability, duration of solution on the wound (soaking time [ST]), negative pressure values (vacuum pressure [VP]), and duration of negative pressure delivery (vacuum time [VT]).

The aim of this study was to establish recommendations for the use of NPWTi therapy in our hospital based on evidence on effectiveness, safety, and efficiency, the consensus guidelines available in the literature, and the verified stability of all the instillation solutions.

## Methods

### Effectiveness, safety, and efficiency of NPWTi

We conducted a literature search for clinical studies published in the last 30 years that had assessed the effectiveness, safety, and efficiency of NPWTi therapy. The PubMed and Cochrane databases were searched using the keywords "drug instillation", "wound", "infection", "negative pressure wound therapy", "closure", "vacuum", and "anti-infective agents". The search was not limited by language, year of publication, or type of publication.

### Consensus guidelines on NPWTi

We conducted a bibliographic search for any international consensus guidelines with specific recommendations on NPWTi therapies that had been published in the last 30 years. The PubMed and Cochrane databases were searched using the keywords "instillation drug", "wound", "infection", "negative pressure wound therapy", "closure", "vacuum", "anti-infective agents", "international", "consensus", and "guidelines". This search was not limited by language, year of publication, or type of publication. We only selected guidelines that were agreed by multi-disciplinary consensus based on the review of the available literature and the clinical experience of the team members themselves.

### Level of evidence

The level of evidence of studies and reviews on effectiveness, safety, and efficiency of NPWTi therapies was established using the Evidence Rating Scale for Therapeutic Studies of the American Society of Plastic and Reconstructive Surgery (ASPS)<sup>10</sup>, which classifies the level of evidence into 5 categories (I to V) according to the study design (Table 1).

### Use recommendations for NPWTi

Based on the available literature on effectiveness, safety, and efficiency, the consensus guidelines, and the verified physicochemical stability of all the instillation solutions, we drafted a set of use recommendations for NPWTi in all patients beginning local treatment of the wound. Each antiseptic or antibiotic used for instillation was classified according to brand name, mechanism and range of action, dose and dosage, reconstitution conditions, vehicle, total preparation volume, physical and chemical stability at room temperature, VP, VT, ST, and the available evidence on effectiveness, safety, and efficiency. We only included the antiseptics and antibiotics available for instillation in NPWTi treatment listed in the pharmacotherapeutic guide of the hospital. Recommendations related to the stability of the instillation solutions were based on the Summary of Product Characteristics, the Stablis database<sup>11</sup>, USP Chapter 797<sup>12</sup>, and information on the stability of parenteral preparations<sup>13</sup>.

## Results

### Effectiveness, safety, and efficiency of NPWTi

After the bibliographic review of clinical trials associated with the use of NPWTi, 13 articles were selected; these appear in Table 2 ordered by their level of evidence. Those articles dealing only with NPWT were excluded, as well as those about NPWTi where the type of instillation solution was not mentioned, or where saline was used exclusively.

Five of the studies referenced (Table 2) were comparative cohort studies (Level of Evidence II and III)<sup>14-18</sup>, and the rest were from series of cases (Level of Evidence IV)<sup>3,6-8,19-22</sup>.

In the cohort studies, NPWTi therapy (solutions: silver nitrate or polyhexanide) was compared with standard treatment (debridement, moist wound healing, oral and/or intravenous antibiotic therapy) or NPWT. In terms of efficacy and safety, comparative studies showed statistical significance towards instillation therapies (NPWTi), regarding clinical variables such as infection recurrence<sup>14</sup>, length of hospital stay<sup>14,16,18</sup>, time for wound

**Table 1.** Classification Scale of Levels of Evidence for Therapeutic Studies According to the American Society of Plastic and Reconstructive Surgery<sup>10</sup>

Evidence	Studies included
Level I	<b>Highest-quality:</b> multi-centre or single-centre randomized controlled trial with adequate power, or systematic review of these studies.
Level II	Prospective cohort or comparative randomized controlled trial, or systematic review of these studies.
Level III	Retrospective cohort or comparative study, case-control study, or systematic review of these studies.
Level IV	Case control series.
Level V	Expert opinion via consensus, clinical case report, or evidence based on physiology, laboratory research, or "first principles".

**Table 2.** Effectiveness, Safety, and Efficiency of NPWTi

Author/s, y	Level of evidence	Sample size	Type of population and study design	Results
Timmers <i>et al.</i> <sup>14</sup> (2009)	II	124 C: 94 I: 30	Post-traumatic osteomyelitis Prospective cohort study C: Standard treatment I: NPWTi + debridement/IV antibiotic solution: polyhexanide; ST: 10-15 min; VP: 300-600 mmHg; VT: NR; days of treatment: 6-60	C vs I; P < 0.0001 Recurrence of osteomyelitis (%): 58.5 vs 10.0 Hospital stay (median, d): 73 vs 36
Gabriel <i>et al.</i> <sup>15</sup> (2008)	II	30 C: 15 I: 15	Complex infected wounds Prospective cohort study C: standard treatment I: NPWTi + IV antibiotic solution: silver nitrate; ST: 30 s; VP: 125 mmHg; VT: 2 h; days of treatment: 2-20	C vs I; P < 0.001 Days of treatment, mean: 36.5 vs 9.9; Days to resolution of infection, mean: 25.9 vs 6.0 Days to wound closure, mean: 29.6 vs 13.2
Kim <i>et al.</i> <sup>16</sup> (2015)	II	100 C: 51 I: 49	Infected wounds Non-inferiority prospective cohort study C: NPWTi; solution: polyhexanide + betaine I: NPWTi; solution: saline solution ST: 20 min; VP: 125 mmHg; VT: 2 h; days of treatment: NR	C vs I Hospital stay, mean, d: 14.5 vs 13.6; P = 0.68 Wound closure (%): 92.2 vs 85.7; P=0.35
Goss <i>et al.</i> <sup>17</sup> (2014)	II	16 C: 8 I: 8	Wounds with significant bacterial load Prospective cohort study C: NPWT I: NPWTi; solution: Dakin's; ST: 10 min; VP: 125 mmHg; VT: 60 min; days of treatment: 7	C vs I; P = 0.016 Absolute bacterial load reduction after 7 d -28.7 x 10 <sup>6</sup> vs 10.6 x 10 <sup>6</sup>
Gabriel <i>et al.</i> <sup>18</sup> (2014)	III	82 C: 34 I: 48	Wounds of the trunk and extremities Retrospective cohort study, cost analysis C: NPWT I: NPWTi; solution: polyhexanide or physiological saline; ST: 10 min; VP: 125 mmHg; VT: 60 min; days of treatment: 7	C vs I; P < 0.0001 Debridements, mean: 4.4 vs 2.0 Hospital stay, mean, d: 27.4 vs 8.1 Wound closure time, mean, d: 20.9 vs 4.1 Therapy cost, mean: \$2,217 vs \$799
Schintler <i>et al.</i> <sup>19</sup> (2009)	IV	15	Soft tissue infection and necrotizing fasciitis Case series NPWTi; solution: polyhexanide; ST: 20 min; VP and VT: NR; days of treatment: 4-18	100% resolution of infections and complete wound healing
Köster <sup>20</sup> (2009)	IV	10	Hip prosthesis infection Case series NPWTi; solution: polyhexanide; ST: 10-15 min; VP: NR; VT: 45-60 min; days of treatment: 3-9	90% resolution of infections; 1 case of reinfection
Lehner <i>et al.</i> <sup>21</sup> (2011)	IV	32	Post-hip arthroplasty infection Case series NPWTi; solution: polyhexanide and saline; ST: 5-30 min; VP: 125-200 mmHg; VT: 30-270 min; days of treatment: 9-46	Treatment success rate: 86% (acute infection), 80% (chronic infection)
Schreiner <i>et al.</i> <sup>22</sup> (2013)	IV	11	Complex wound infection Case series NPWTi; solution: polyhexanide; ST: 18 min; VP: 75-150 mmHg; VT: 2 h; days of treatment, mean: 6.5	10/11 were healed; no recurrence of wound infection

**Table 2. (cont.). Effectiveness, Safety, and Efficiency of NPWTi**

Author/s, y	Level of evidence	Sample size	Type of population and study design	Results
Fleischmann <i>et al.</i> <sup>3</sup> (1998)	IV	27	Acute osteomyelitis Case series NPWTi; solution: antiseptic or antibiotic; ST: 30 min; VP: 150-600 mmHg; VT: 3 h; days of treatment: 7	Immediate wound closure: 81%; 1 recurrence of osteomyelitis
Wolvos <sup>8</sup> (2004)	IV	5	Infections after amputation Case series NPWTi; solution: vancomycin, gentamicin, tobramycin; ST: 5 min; VP: 125 mmHg; VT: 3 h; days of treatment: 5-24	Less pain (1), healing (4)
Bernstein and Tam <sup>7</sup> (2005)	IV	5	Post-surgery diabetic foot wound Case series NPWTi; solution: polymyxin B/bacitracin; ST: 5 min; VP: 125 mmHg; VT: 6 h; days of treatment: 2-9	Healing (5)
Kirr <i>et al.</i> <sup>6</sup> (2006)	IV	5	Post-endoprosthesis infection Case series NPWTi; solution: bacitracin/neomycin; ST: 10-20 min; VP: NR; VT: 60 min; days of treatment: 15	100% resolution of the infection

C: control group; I: intervention group; IV: intravenous; NPWT: negative pressure wound therapy; NPWTi: negative pressure wound therapy with instillation; NR: not reported; ST: soaking time of antiseptic/antibiotic; VP: vacuum pressure; VT: vacuum time.

healing<sup>15,18</sup> or the absolute reduction in bacterial load in the infection bed<sup>17</sup>. Specifically, the study by Gabriel *et al.*<sup>18</sup> (n=82) appears interesting; besides efficacy and safety, there was also an evaluation of NPWTi therapy (with polyhexanide or saline) vs. NPWT, and the conclusion was favorable to therapy with instillation.

In the rest of non-comparative studies, we found cases of antiseptic solution instillation (polyhexanide)<sup>19,22</sup> and other studies where antibiotic solutions were applied, specifically neomycin / bacitracin<sup>6</sup> (n=5), polymyxin B/bacitracin<sup>7</sup> (n=5) or vancomycin<sup>8</sup> (n=5). As shown in Table 2, VP, VT and RT were different for each type of study, showing that there is no consensus or standard practice for this therapy.

## Consensus guidelines on NPWTi

After the literature review, we found 2 expert consensus recommendations on NPWTi<sup>2,23</sup>. In both cases, multidisciplinary teams comprising general, orthopedic, vascular, and plastic surgeons from the United States and Europe were asked to provide consensus guidelines on the appropriate use of negative pressure therapy with instillation. Several face-to-face meetings were held in which the team discussed the available evidence and individual clinical experience. The final recommendations on the use of NPWTi therapy were the result of agreements reached by over 80% of the members. The 2013 recommendations<sup>22</sup> stated that 12 professionals took part in the meetings, whereas the 2015 recommendations provided no information on this aspect<sup>9</sup>. No guidelines were provided on the instillation of antibiotics or on the stability of antibiotic or antiseptic solutions. Based on the opinions of both teams, we created the following use recommendations (Table 3).

According to the 2013 consensus<sup>22</sup>, NPWTi would be appropriate for different types of wounds (Table 3). Regarding instillation solutions, the 2013 recommendations supported the use of polyhexanide and hydrogen peroxide, whereas the 2015 recommendations supported the instillation of physiological saline solution. The 2013 recommendations established a VP of -125 mmHg to -150 mmHg, whereas the 2015 recommendations suggested a VP of -125 mmHg alone. The recommended VT varied between 1 hour and 4 hours, but consensus was achieved on an ST of 10 minutes to 20 minutes (see Table 3).

It should be noted that both meetings were sponsored by an instillation device manufacturer, who also selected the team members. Thus, there could be potential conflicts of interest in the 2 studies.

## Use recommendations for NPWTi

Based on the available evidence on effectiveness, safety, and efficiency and on the consensus guidelines, we proposed and established some use recommendations to be implemented in our hospital (Table 4). After initiating NPWTi therapy, microbiological samples should be taken from the wound bed every 72 hours to 96 hours. Whenever possible, cultures should be taken during debridement or wound cleaning in the operating room. The duration of treatment with NPWTi therapy should be guided by the clinical judgement of the health professional depending on the status of wound closure, confirmation of negative microbiological growth in 2 or more consecutive samples, or the wound being prepared for a grafting procedure<sup>22</sup>.

## Discussion

The review shows that there is limited evidence in the literature in support of NPWTi. We established some use recommendations based on the classification of the level of evidence of the references and experts opinions mentioned above.

The updated data on antimicrobial solution stability provide added value to patient care by increasing the safety of the process without compromising the effectiveness of the therapy.

The authors are fully aware of the limitations of this study. Firstly, these recommendations are limited to the specific situation of our hospital; thus, it may not be possible to extrapolate them to other settings or professional users. Secondly, this article does not report the results of implementing these recommendations, since the study was restricted to issuing guidelines based on the literature review and expert opinions. Finally, it should also be mentioned that some publications, especially the reviews and consensus opinions, were sponsored and funded by the American manufacturer of the devices, which may involve potential conflicts of interest in their recommendations.

Therefore, further research is needed to determine which instillation solutions are the most suitable in given clinical settings, particularly in the field of antimicrobials, for which there is very limited information.

Although this article establishes a set of updated recommendations on VP, VT, and ST, new studies are required to confirm whether these recommendations are generalizable, or if, on the contrary, exceptions should be made according to the clinical situation

## Funding

No funding.

## Conflicts of interests

No conflict of interests.

## Contribution to the scientific literature

This article provides preliminary guidelines on the application of negative pressure therapy with instillation based on evidence regarding its effectiveness, safety, and efficiency and according to the consensus guidelines available in the literature. These recommendations were also based on a review of the physicochemical stability of the antiseptic and antimicrobial solutions most commonly used for instillation. This information is typically requested by prescribing physicians.

The contribution of this review is to increase awareness of the recommendations for negative pressure therapy with instillation among health professionals in their clinical practice. The correct and rational use of available resources would lead to better health outcomes.

**Table 3.** Consensus on NPWTi

NPWTi Consensus	Ratio of acceptance, 2013 guidelines <sup>22</sup>	Ratio of acceptance, 2015 guidelines <sup>9</sup>
<b>Types of wound</b>		
Acute and chronic infected wounds	12/12 (100%)	NE
Contaminated wounds	12/12 (100%)	NE
Diabetic wounds	12/12 (100%)	NE
Traumatic wounds	12/12 (100%)	NE
Pressure ulcers	11/12 (92%)	NE
Wounds with exposed bone	12/12 (100%)	NE
Wounds with underlying osteomyelitis	12/12 (100%)	NE
Wounds with orthopedic material or implants	12/12 (100%)	NE
Painful wounds	10/12 (83%)	NE
Wounds before amputation	10/11 (91%)	NE
<b>Suitable instillation solution</b>		NE
0.10% polyhexanide + betaine (Prontosan®)	12/12 (100%)	NE
0.04% polyhexanide (Lavasept®)	12/12 (100%)	NE
Super-oxidized solution (Microcyn/Dermacyn®)	8/9 (89%)	NE
0.90% saline solution	6/11 (55%)	Yes
<b>Appropriate Soaking time</b>		
10 min	11/12 (92%)	Yes
20 min	10/11 (91%)	Yes
<b>Appropriate vacuum pressure</b>		
-125 mmHg	12/12 (100%)	Yes
-150 mmHg	10/12 (83%)	NE
<b>Appropriate vacuum time</b>		
1.0 h	10/11 (91%)	NE
2.0 h	10/12 (83%)	Yes
2.5 h	10/11 (91%)	NE
4.0 h	8/11 (73%)	Yes

NE: not evaluated.

**Table 4.** Recommendations for the Use of Antimicrobials and Antiseptics in NPTWI

Antibiotic/ Antiseptic	Trade name	Dose	Reconstitution	Delivery vehicle	Total volume	PC stability at RT (25°C)	Vacuum pressure	Instillation soaking time	Mechanism of action/ spectrum	Effectiveness/ safety/efficiency
Amikacin	Amikacin Braun® 500 mg/2 mL vial	500 mg	NA	100-200 mL, Saline/ D5%	102- 202 mL	24 h	-125 mmHg and -150 mmHg	10-20 min	Bacterial protein synthesis inhibitor (Gram -, including <i>Pseudomonas</i> )	No data available
Caspofungin	Cancidas® 50 mg and 70 mg powder vial	50 or 70 mg	10.5 mL WFI	100-250 mL saline	110- 260 mL	24 h	-125 mmHg and -150 mmHg	10-20 min	Inhibitor of yeast and fungal cell wall synthesis ( <i>Aspergillus</i> and <i>Candida</i> )	No data available
Ciprofloxacin	Ciprofloxacin Normon® 200 mg/100 mL bag for infusion	200 mg	NA	NA	100 mL	9 d	-125 mmHg and -150 mmHg	10-20 min	Inhibitor of bacterial DNA synthesis (Gram+ and Gram -, including <i>Pseudomonas</i> )	No data available
Colistin	Colistimethate Sodium G.E.S.® 1 million IU powder vial	1 MIU (80 mg)	10.0 mL WFI	50 mL Saline/ D5%	60 mL	8 h	-125 mmHg and -150 mmHg	10-20 min	Modifies the permea- bility of bacterial membrane (Gram -)	No data available
Fluconazole	Diflucan® 200 mg/100 mL solution for infusion	200 mg	NA	NA	100 mL	No data available (discard after insti- llation)	-125 mmHg and -150 mmHg	10-20 min	Inhibitor of cellular ergosterol synthesis ( <i>Candida</i> , <i>Cryptococ- cus</i> , <i>Blastomyces</i> , etc.)	No data available
Gentamicin	Gentamicin Braun® 240 mg/80 mL solution for infusion	240 mg	NA	NA	80 mL	24 h	-125 mmHg and -150 mmHg	10-20 min	Bacterial protein synthesis inhibitor (Gram - including <i>Pseudomonas</i> )	<b>Wolvos</b> <sup>8</sup> (2004), <i>n</i> =5, 4/5 healed  <b>Timmers et al.</b> <sup>14</sup> (2009) <i>n</i> =124. Case-control study. Decreased infection recu- rence, fewer surgeries, and decrease in hospital stay in the instillation group (polyhexa- nide). <b>Gabriel et al.</b> <sup>18</sup> (2014) <i>n</i> =82. Case-control study. Decreased hospital stay and early closure of the wound in the instillation group (polyhexa- nide) <b>Lehner et al.</b> <sup>21</sup> (2009) <i>n</i> =32. No explanation of the infected orthopedic implant needed
Polyhexanide	Prontosan® 0.1% solution for irrigation	300 mg	NA	NA	350 mL	8 wk	-125 mmHg and -150 mmHg	10-20 min	Antiseptic	
Tobramycin	Tobramycin Braun® 240 mg/80 mL solution for infusion	240 mg	NA	NA	80 mL	48 h	-125 mmHg and -150 mmHg	10-20 min	Bacterial protein synthesis inhibitor (Gram -, including <i>Pseudomonas</i> )	<b>Wolvos</b> <sup>8</sup> (2004), <i>n</i> =5, 4/5 healed
Vancomycin	Vancomycin Normon® 500 mg vial	500 mg	10.0 mL WFI	100-250 mL SF/G5%	110- 260 mL	24 h	-125 y -150 mmHg	10-20 min	Inhibition of bacterial cell wall synthesis (Gram + [MRSA])	<b>Wolvos</b> <sup>8</sup> (2004), <i>n</i> =5, 4/5 healed

D5%: 5% dextrose solution; MRSA: methicillin-resistant *Staphylococcus aureus*; NA: not applicable; PC: physicochemical; RT: room temperature; Saline: 0.9% saline; WFI: water for injection.

## Bibliography

- Hess C. Clinical Guide to Skin and Wound Care. 7<sup>a</sup> ed. Ambler (Pensilvania): Lippincott Williams & Wilkins; 2012.
- Miller MS. Negative pressure wound therapy. In: Farrar D. Advanced Wound Repair Therapies. Cambridge (United Kingdom): Woodhead publishing; 2011. p. 587-605.
- Fleischmann W, Russ M, Westhauser A, Stampehl M. Vacuum sealing as carrier system for controlled local drug administration in wound infection. *Unfallchirurg*. 1998;101(8):649-54. DOI: 10.1007/s001130050318
- Apelqvist J, Armstrong DG, Augustin M, Baharestani M, Banwell P, Dalla Paola L, et al. Vacuum assisted closure: recommendations for use. A consensus document. *Int Wound J*. 2008;5(Supl 4):iii-19. DOI: 10.1111/j.1742-481X.2008.00537.x
- Back DA, Scheuermann-Poley C, Willy C. Recommendations on negative pressure wound therapy with instillation and antimicrobial solutions - when, where and how to use: what does the evidence show? *Int Wound J*. 2013;10(Supl 1):S32-42. DOI: 10.1111/iwj.12183
- Kirr R, Wiberg J, Hertlein H. Clinical experience and results of using the V.A.C. instill therapy in infected hip- and knee prosthetics. *Zentralbl Chir*. 2006;131(Supl 1):S79-82. DOI: 10.1055/s-2005-921501
- Bernstein BH, Tam H. Combination of Subatmospheric Pressure Dressing and Gravity Feed Antibiotic Instillation in the Treatment of Post-Surgical Diabetic Foot Wounds: A Case Series. *Wounds*. 2005;17(2):37-48.
- Wolvos T. Wound instillation-the next step in negative pressure wound therapy. Lessons learned from initial experiences. *Ostomy Wound Manage*. 2004;50(11):56-66.
- Kim PJ, Attinger CE, Crist BD, Gabriel A, Galiano RD, Gupta S, et al. Negative Pressure Wound Therapy With Instillation: Review of Evidence and Recommendations. *Wounds*. 2015;27(12):S2-19.
- Health & Human Services. American Society of Plastic Surgeons. [web page] U.S.A. [updated 12/5/2017; accessed 22/4/2018]. Available at: <https://www.plasticsurgery.org/>
- Infostab. Estabilidad y compatibilidad de los medicamentos. Lista de la molécula. [Web database] [updated 1/3/2018; accessed 1/3/2018]. Available at: <http://www.stabilis.org/Monographie.php?liste>
- Pharmaceutical compounding: sterile preparations (Chapter 797). In: The United States Pharmacopeia (USP). 1<sup>a</sup> ed. The United States Pharmacopeial Convention; 2008.
- Gaspar Carreño M, Torrico Martín F, Novajarque Sala L, Batista Cruz M, Ribeiro Gonçalves P, Porta Oltra B, et al. Medicamentos de Administración Parenteral: Recomendaciones de preparación, administración y estabilidad. *Farm Hosp*. 2014;38(6):461-7. DOI: 10.7399/fh.2014.38.6.7524
- Timmers MS, Graafland N, Bernards AT, Nelissen RG, van Dissel JT, Jukema GN. Negative pressure wound treatment with polyvinyl alcohol foam and polyhexanide antiseptic solution instillation in posttraumatic osteomyelitis. *Wound Repair Regen*. 2009;17(2):278-86. DOI: 10.1111/j.1524-475X.2009.00458.x
- Gabriel A, Shores J, Heinrich C, Baqai W, Kalina S, Sogioka N, et al. Negative pressure wound therapy with instillation: a pilot study describing a new method for treating infected wounds. *Int Wound J*. 2008;5(3):399-413. DOI: 10.1111/j.1742-481X.2007.00423.x
- Kim PJ, Attinger CE, Oliver N, Garwood C, Evans KK, Steinberg JS, et al. Comparison of outcomes for normal saline and an antiseptic solution for negative pressure wound therapy with instillation. *Plast Reconstr Surg*. 2015;136:657e-64e. DOI: 10.1097/PRS.0000000000001709
- Goss SG, Schwartz JA, Facchin F, Avdagic E, Gendics C, Lantis JC 2nd. Negative pressure wound therapy with instillation (NPWTi) better reduces post-debridement bioburden in chronically infected lower extremity wounds than NPWT alone. *J Am Coll Clin Wound Spec*. 2014;4(4):74-80. DOI: 10.1016/j.jccw.2014.02.001
- Gabriel A, Kahn K, Karmy-Jones R. Use of negative pressure wound therapy with automated, volumetric instillation for the treatment of extremity and trunk wounds: clinical outcomes and potential cost-effectiveness. *Eplasty*. 2014;14:e41.
- Schintler MV, Prandl EC, Kreuzwirt G, Grahmann MR, Spendel S, Scharnagl E. The impact of V.A.C. Instill in severe soft tissue infections and necrotizing fasciitis. *Infection*. 2009;37(Supl 1):31-6.
- Köster G. Management of early periprosthetic infections in the knee using the vacuum-instillation therapy. *Infection*. 2009;37(Supl 1):S18-20.
- Lehner B, Weiss S, Suda J, Witte D. Application of V.A.C. Instill<sup>®</sup> therapy in case of periprosthetic infection in hip arthroplasty. *Infection*. 2009;37(Supl 1):S13-7.
- Schreiner W, Oster O, Stapel P, Sirbu H. [V. A. C. Instill<sup>®</sup> therapy - new option in septic thoracic surgery]. *Zentralbl Chir*. 2013;138(1):117-20. DOI: 10.1055/s-0032-1315201
- Kim PJ, Attinger CE, Steinberg JS, Evans KK, Lehner B, Willy C, et al. Negative-Pressure Wound Therapy with Instillation: International Consensus Guidelines. *Plast Reconstr Surg*. 2013;132(6):1569-79. DOI: 10.1097/PRS.0b013e3182a80586